ABSTRACT
Emerging evidence implicates the role of inflammation and immunity in autism. However, little is known about the involvement of specific immunological pathways and their causal role. In 18,381 autism cases and 27,969 controls from the PGC and the iPSYCH consortia, we investigated whether 15 cytokines implicated in the differentiation and function of CD4+ T cell subsets (TH1, TH2, TH9, TFH, TH17, TReg) could be causally linked to autism. Within a Mendelian randomization framework, we used protein quantitative trait loci (pQTLs; N=1,000-3,394) to assess the effects of genetically proxied levels of plasma cytokines on autism. We additionally used brain cortex expression quantitative trait loci (eQTLs; N= 6,601) to investigate whether genetically predicted expression of the genes encoding the cytokines of interest influence autism. We performed colocalisation to assess the possibility that the identified effects were confounded due to Linkage Disequilibrium (LD). We also assessed the possibility of reverse causation. We report consistent evidence for causal effects of genetically predicted levels of IFN-γR1, IL-12Rβ1 (TH1), and IL-4RA, IL-5RA, IL-13RA1 (TH2) on autism. We identified brain-specific effects of genetically predicted expression of IFNGR1, IL12RB1, IL23A, which in the case of IFNGR1 and IL23A were additionally supported by evidence suggestive of colocalisation. Findings appeared unlikely to be influenced by reverse causation. Our findings are consistent with a potentially causal effect of TH1 and TH2 pathway cytokines in autism, and further research is required to elucidate the pathways via which TH1 and TH2 influence its phenotypic presentation.
Competing Interest Statement
JWR receives funding from Biogen for research unrelated to the present study. No funding body has influenced data collection, analyses or their interpretation.
Funding Statement
The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [, MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5]. This research was funded in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. CD acknowledges the support of Wellcome Trust [215379/Z/19/Z]. GDS, HJ, DR, SS, SZ are supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. GMK acknowledges funding support from the Wellcome Trust (201486/Z/16/Z), the MQ: Transforming Mental Health (grant code: MQDS17/40), the Medical Research Council UK (grant code: MC_PC_17213 and grant code: MR/S037675/1), NIHR (project code: NIHR202646), and the BMA Foundation (J Moulton grant 2019). JWR is funded by Biogen. The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIMH (1U01MH109514-01) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark. RG acknowledges funding support from the Swedish Research Council (VR2017-02900). AH was supported by grants from the South-Eastern Norway Regional Health Authority (2020022, 2018059) and the Research Council of Norway (274611, 288083).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ALSPAC data: ethical approval was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. GWAS data: across all analyses summary data were used. These data are publicly available for research purposes. Details on the ethics declarations for each GWAS study can be found in the original publications: Grove et al., 2019; Sun et al., 2018; Suhre et al., 2017; Folkersen et al., 2017; Emilsson et al., 2018; de Klein et al., 2021
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵● The iPSYCH Autism Spectrum Disorder working group: Anders D. Børglum, Jakob Grove, Thomas Damm Als, Thomas Werge, Preben Bo Mortensen, Marianne Giørtz Pedersen, Carsten Bøcker Pedersen, Ole Mors, Merete Nordentoft, David M. Hougaard, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, Christine Søholm Hansen
Data Availability
Summary data used to conduct the present analyses can be found at: https://gwas.mrcieu.ac.uk/, https://metabrain.nl, https://www.med.unc.edu/pgc/download-results/. Summary data on autism excluding intellectual disabilities can be obtained after application to the iPSYCH Autism Spectrum Disorder working group.